OBJECTIVE： To systematically review the efficacy and safety of the generic and original preparation of atorvastatin， and provide evidence-based reference for clinical treatment. METHODS： Retrieved from PubMed， EMBase， Cochrane Library， CJFD， Wanfang Database， VIP and CBM， related randomized controlled trials （RCT） about generic preparation of atorvastatin （test group） versus original preparation of atorvastatin （control group） were collected. Meta-analysis was performed by using Rev Man 5.3 software after data extract and quality evaluation. RESULTS： Totally 16 RCTs were included， involving 2 077 patients. Results of Meta-analysis showed， compared with control group， there were no significant differences in reducing total cholesterol （TC） [MD＝－0.06，95％CI（－0.14，0.01），P＝0.11]， triglyceride （TG） [MD＝－0.00，95％CI（－0.08，0.08），P＝0.99]， low-density lipoprotein cholesterol （LDL-C） [MD＝－0.07，95％CI（－0.16，0.01），P＝0.09]， increasing high-density lipoprotein cholesterol （HDL-C） [MD＝－0.00，95％ CI（－0.03，0.03），P＝0.96] and the incidence of major adverse cardiac events （MACE） [OR＝1.18，95％CI（0.71，1.97），P＝0.52] in test group； in terms of safety， compared with control group， there were no significant differences in the resulting in alanine aminotransferase （ALT） increased [OR＝1.08，95％CI（0.51，2.30），P＝0.83]， the incidences of myalgia [OR＝2.46，95％CI（0.70，8.65），P＝0.16] and gastrointestinal adverse reactions [OR＝1.11，95％CI（0.64，1.95），P＝0.71]. CONCLUSIONS： Both the generic and original preparation of atorvastatin can effectively reduce blood lipid levels， with similar safety.